Immunotherapy plus fasting diet and vitamin C for KRAS-mutated colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) plus a fasting-mimicking diet and high-dose vitamin C for people with a specific type of advanced colorectal cancer (KRAS-mutated). It aims to see if this approach can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer has spread to other parts of the body (like the liver or lungs) and has a change in the KRAS gene.
- You have already tried at least one type of standard chemotherapy, and it either didn't work, caused side effects, or you couldn't take it.
- You are 18 years or older, able to care for yourself, and have a life expectancy of at least 3 months.
- You don't have diabetes, and you are not currently taking vitamin C supplements.
- You are willing to follow a special fasting-mimicking diet during the study, and you can safely stop certain medications during the fasting periods.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This trial is testing a combination of two targeted drugs (panitumumab and sotorasib) with a chemotherapy drug (5-fluorouracil) for people with advanced colorectal cancer that has a specific KRAS G12C mutation and who cannot receive stronger chemotherapy. It aims to see if this treatment can help control the cancer.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests a combination of two immunotherapy drugs to see if they can stop colorectal cancer from returning after standard treatment. It is for people who still have cancer DNA in their blood after surgery and/or chemotherapy, which means they are at high risk of the cancer coming back.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Hear when a new Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.